Literature DB >> 26843290

Hypertension: Benefits of strict blood-pressure lowering in hypertension.

Kazuomi Kario1.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 26843290     DOI: 10.1038/nrcardio.2016.13

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  9 in total

1.  Redefining Blood-Pressure Targets--SPRINT Starts the Marathon.

Authors:  Vlado Perkovic; Anthony Rodgers
Journal:  N Engl J Med       Date:  2015-11-09       Impact factor: 91.245

2.  Home blood pressure and cardiovascular outcomes in patients during antihypertensive therapy: primary results of HONEST, a large-scale prospective, real-world observational study.

Authors:  Kazuomi Kario; Ikuo Saito; Toshio Kushiro; Satoshi Teramukai; Yusuke Ishikawa; Yoshihiro Mori; Fumiaki Kobayashi; Kazuyuki Shimada
Journal:  Hypertension       Date:  2014-08-25       Impact factor: 10.190

3.  A new initiative on precision medicine.

Authors:  Francis S Collins; Harold Varmus
Journal:  N Engl J Med       Date:  2015-01-30       Impact factor: 91.245

Review 4.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.

Authors:  Dena Ettehad; Connor A Emdin; Amit Kiran; Simon G Anderson; Thomas Callender; Jonathan Emberson; John Chalmers; Anthony Rodgers; Kazem Rahimi
Journal:  Lancet       Date:  2015-12-24       Impact factor: 79.321

5.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

6.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

7.  Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  N Engl J Med       Date:  2014-08-30       Impact factor: 91.245

8.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

Authors:  Jackson T Wright; Jeff D Williamson; Paul K Whelton; Joni K Snyder; Kaycee M Sink; Michael V Rocco; David M Reboussin; Mahboob Rahman; Suzanne Oparil; Cora E Lewis; Paul L Kimmel; Karen C Johnson; David C Goff; Lawrence J Fine; Jeffrey A Cutler; William C Cushman; Alfred K Cheung; Walter T Ambrosius
Journal:  N Engl J Med       Date:  2015-11-09       Impact factor: 91.245

Review 9.  Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis.

Authors:  Alastair J S Webb; Urs Fischer; Ziyah Mehta; Peter M Rothwell
Journal:  Lancet       Date:  2010-03-13       Impact factor: 79.321

  9 in total
  3 in total

Review 1.  The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.

Authors:  Kazuomi Kario
Journal:  Curr Cardiol Rep       Date:  2018-01-27       Impact factor: 2.931

Review 2.  Systemic Hemodynamic Atherothrombotic Syndrome and Resonance Hypothesis of Blood Pressure Variability: Triggering Cardiovascular Events.

Authors:  Kazuomi Kario
Journal:  Korean Circ J       Date:  2016-07-21       Impact factor: 3.243

3.  Nocturnal hypertension in diabetes: Potential target of sodium/glucose cotransporter 2 (SGLT2) inhibition.

Authors:  Kazuomi Kario; Michael Weber; Ele Ferrannini
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-02-19       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.